Does Skyrizi Help with Joint Pain?
Skyrizi (risankizumab-rzaa) treats psoriatic arthritis (PsA), a condition causing joint pain, swelling, and stiffness alongside psoriasis. In clinical trials, patients with active PsA saw significant improvements: 36-40% achieved at least 20% reduction in joint pain and swelling (ACR20 response) after 24 weeks, compared to 20% on placebo. Joint pain scores dropped notably in responders.[1][2]
How Does Skyrizi Target Joint Pain in PsA?
Skyrizi blocks interleukin-23 (IL-23), a cytokine driving inflammation in PsA. This reduces joint inflammation directly. Trials showed sustained relief: up to 57% hit ACR50 (50% improvement) by week 52, with many maintaining low disease activity or remission. It works for both skin and joints, unlike some psoriasis drugs.[1][3]
What Do Real Patients Report on Joint Pain Relief?
Patient reviews often note faster, lasting joint pain reduction versus older biologics. Common feedback: pain eases within weeks, improving mobility. Some report near-complete relief after 6 months, though a minority see minimal change or injection-site reactions.[4]
How Does Skyrizi Compare to Other PsA Treatments?
| Drug | Joint Pain Response (ACR20 at 24 weeks) | Key Difference |
|------|-----------------------------------------|---------------|
| Skyrizi | 36-40% | Targets IL-23; strong skin-joint dual benefit |
| Humira (adalimumab) | 39-50% | TNF blocker; broader approval but higher infection risk |
| Cosentyx (secukinumab) | 50-51% | IL-17 blocker; faster skin clearance, similar joints |
| Tremfya (guselkumab) | 58-70% | Fellow IL-23; slightly higher response rates |
Skyrizi matches or exceeds TNF inhibitors for joints while having fewer serious side effects in head-to-head data.[1][5]
When Does Joint Pain Relief Start and Last?
Onset: Joint improvements appear by week 4-12, peaking at 24 weeks. Duration: Effects hold through 2+ years with every-12-week dosing. If no response by week 16-24, doctors often switch.[2][3]
Common Side Effects Tied to Joint Use
Upper respiratory infections (15%), headaches (10%), and fatigue (6%) occur most. Joint pain rarely worsens; serious infections or liver issues are uncommon (<1%). Monitor for allergic reactions.[1]
Who Qualifies for Skyrizi for Joint Pain?
FDA-approved for adults with active PsA, including those who've tried one or more TNF blockers. Not for standalone osteoarthritis or rheumatoid arthritis without psoriasis. Requires specialist prescription; covered by most insurance with prior auth.[1][6]
[1]: Skyrizi Prescribing Information (FDA)
[2]: KEEPsAKE 1 Trial (Lancet, 2020)
[3]: KEEPsAKE 2 Trial (Rheumatology, 2021)
[4]: Patient reviews aggregated from Drugs.com and WebMD
[5]: Cosentyx/Skyrizi comparison in PsA meta-analysis (JAMA Dermatol, 2022)
[6]: AbbVie (Skyrizi manufacturer) eligibility criteria